Abstracts tagged "Rheumatic disease and vaccines"

Abstract Number: 1222 • 2018 ACR/ARHP Annual Meeting
Suboptimal Immunization Coverage Among Rheumatology Patients in Routine Clinical Care
Tedi Qendro¹, María Laura de la Torre², Pantelis Panopalis³, Elizabeth Hazel⁴, Ines Colmegna⁵ and Marie Hudson⁶, ¹Medicine, McGill University, Montreal, QC, Canada, ²Internal Medicine, Rheumatology and Immunology, CEMIC, Buenos Aires, Argentina, ³Division of Rheumatology, McGill University, Montreal, QC, Canada, ⁴Rheumatology, McGill University Health Centre, Pointe-Claire, QC, Canada, ⁵The Research Institute of the McGill University Health Centre, Division of Rheumatology, Department of Medicine, McGill University, Montreal, Quebec, Canada, Montreal, QC, Canada, ⁶Division of Rheumatology, Jewish General Hospital, Lady Davis Institute for Medical Research, Montreal, QC, Canada
Background/Purpose: Vaccine-preventable infections pose an increased risk of infection and complications in patients with rheumatic diseases. While recommendations highlight the importance of vaccination in this…
Abstract Number: 2028 • 2017 ACR/ARHP Annual Meeting
Compliance with Pneumococcal Vaccination in Rheumatic Disease Patients on Immunosuppressive Medications
Zainab Shahnawaz¹, Fatme Allam² and Andras Perl³, ¹Medicine/Rheumatology, SUNY Upstate Medical University, Syracuse, NY, ²SUNY Upstate Medical University, Syracuse, NY, ³Medicine, SUNY Upstate Medical University, Syracuse, NY
Background/Purpose: The 2012 recommendations of the Centers for Disease Control (CDC) advise that adults aged ≥19 years with immunocompromising conditions including patients on iatrogenic immunosuppression…
Abstract Number: 971 • 2014 ACR/ARHP Annual Meeting
The Long-Term Efficacy of an Anti-Pneumococcal Polysaccharide Vaccine (PPSV23, Pneumovax) Among Autoimmune Inflammatory Rheumatic Patients
Adi Broyde¹, Uri Arad², Noa Madar-Balakinski², Daphna Paran³, Ilana Kaufman⁴, Ira Litinsky⁵, David Levartovsky⁶, Irena Wigler², Dan Caspi⁷ and Ori Elkayam⁸, ¹Department of rheumatology, Tel Aviv medical center, Tel Aviv, Israel, ²Department of Rheumatology, Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, ³Rheumatology, Tel-Aviv Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel, ⁴Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel-aviv, Israel, ⁵Rheumatology, Tel Aviv Sourasky Medical Ctr, Tel-Aviv University, Tel Aviv, Israel, ⁶Department of rheumatology. Tel Aviv Medical Center, Tel Aviv, Israel, ⁷Rheumatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ⁸Rheumatology, Tel-Aviv Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel- Aviv, Israel
Background/Purpose: Vaccination with Pneumovax is recommended for adult patients with auto-immune inflammatory rheumatic diseases (AIIRD). Re-vaccination is recommended after 5 years in this population although…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].